Related Experiment Video
Updated: Jan 23, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Trichostatin A Inhibits Rhabdomyosarcoma Proliferation and Induces Differentiation through MyomiR Reactivation
M Tarnowski1, M Tkacz1, P Kopytko1
1Department of Physiology, Pomeranian Medical University, Szczecin, Poland.
Abstract:
Rhabdomyosarcoma (RMS) is a malignant tumour of soft tissues, occurring mainly in children and young adults. RMS cells derive from muscle cells, which due to mutations and epigenetic modifications have lost their ability to differentiate. Epigenetic modifications regulate expression of genes responsible for cell proliferation, maturation, differentiation and apoptosis. HDAC inhibitors suppress histone acetylation; therefore, they are a promising tool used in cancer therapy. Trichostatin A (TsA) is a pan-inhibitor of HDAC. In our study, we investigated the effect of TsA on RMS cell biology. Our findings strongly suggest that TsA inhibits RMS cell proliferation, induces cell apoptosis, and reactivates tumour cell differentiation. TsA up-regulates miR-27b expression, which is involved in the process of myogenesis. Moreover, TsA increases susceptibility of RMS cells to routinely used chemotherapeutics. In conclusion, TsA exhibits anti-cancer properties, triggers differentiation, and thereby can complement an existing spectrum of chemotherapeutics used in RMS therapy.
Insights
Trichostatin A (TsA) shows promise in treating rhabdomyosarcoma (RMS) by inhibiting cancer cell growth, promoting apoptosis, and restoring differentiation. This HDAC inhibitor may enhance current chemotherapy for RMS.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Rhabdomyosarcoma (RMS) is a pediatric soft tissue cancer arising from muscle cells with impaired differentiation.
- Epigenetic modifications critically influence gene expression in cancer, affecting proliferation, differentiation, and apoptosis.
- Histone deacetylase (HDAC) inhibitors are emerging as a therapeutic strategy in cancer treatment.
Purpose of the Study:
- To investigate the effects of Trichostatin A (TsA), a potent HDAC inhibitor, on rhabdomyosarcoma (RMS) cell biology.
- To determine TsA's impact on RMS cell proliferation, apoptosis, differentiation, and chemosensitivity.
Main Methods:
- Treatment of RMS cells with Trichostatin A (TsA).
- Assessment of cell proliferation, apoptosis, and differentiation markers.
- Analysis of microRNA expression, specifically miR-27b.
- Evaluation of combined treatment effects with standard chemotherapeutics.
Main Results:
- TsA significantly inhibited RMS cell proliferation.
- TsA treatment induced apoptosis in RMS cells.
- TsA reactivated tumor cell differentiation and upregulated miR-27b, a key factor in myogenesis.
- TsA enhanced the sensitivity of RMS cells to conventional chemotherapeutic agents.
Conclusions:
- Trichostatin A (TsA) demonstrates significant anti-cancer properties against rhabdomyosarcoma (RMS).
- TsA's ability to induce differentiation and apoptosis offers a novel therapeutic approach.
- TsA can potentially complement existing chemotherapy regimens for RMS treatment.
Related Concept Videos
Feedback Inhibition
Abnormal Proliferation
Cross-reactivity
Reactivity of Enols
Enzyme Inhibition
Reactivity of Enolate Ions

